- Home
- ACRS vs FSP Comparison
ACRS vs FSP Comparison
Compare ACRS & FSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- FSP
- Stock Information
- Founded
- ACRS 2012
- FSP 1981
- Country
- ACRS United States
- FSP United States
- Employees
- ACRS N/A
- FSP N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- FSP Real Estate Investment Trusts
- Sector
- ACRS Health Care
- FSP Real Estate
- Exchange
- ACRS Nasdaq
- FSP Nasdaq
- Market Cap
- ACRS 170.9M
- FSP 187.5M
- IPO Year
- ACRS 2015
- FSP N/A
- Fundamental
- Price
- ACRS $1.48
- FSP $1.84
- Analyst Decision
- ACRS Strong Buy
- FSP
- Analyst Count
- ACRS 7
- FSP 0
- Target Price
- ACRS $11.67
- FSP N/A
- AVG Volume (30 Days)
- ACRS 1.2M
- FSP 326.7K
- Earning Date
- ACRS 05-06-2025
- FSP 04-29-2025
- Dividend Yield
- ACRS N/A
- FSP 2.19%
- EPS Growth
- ACRS N/A
- FSP N/A
- EPS
- ACRS N/A
- FSP N/A
- Revenue
- ACRS $18,720,000.00
- FSP $120,112,000.00
- Revenue This Year
- ACRS N/A
- FSP $4.36
- Revenue Next Year
- ACRS $425.96
- FSP $0.81
- P/E Ratio
- ACRS N/A
- FSP N/A
- Revenue Growth
- ACRS N/A
- FSP N/A
- 52 Week Low
- ACRS $0.95
- FSP $1.47
- 52 Week High
- ACRS $5.17
- FSP $2.28
- Technical
- Relative Strength Index (RSI)
- ACRS 26.80
- FSP 50.26
- Support Level
- ACRS $1.57
- FSP $1.76
- Resistance Level
- ACRS $1.78
- FSP $1.89
- Average True Range (ATR)
- ACRS 0.10
- FSP 0.07
- MACD
- ACRS 0.02
- FSP 0.00
- Stochastic Oscillator
- ACRS 6.35
- FSP 54.76
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About FSP Franklin Street Properties Corp.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.